Targeted Agents Continue to Advance in MCL, With CAR T on the Horizon
Published: Tuesday, Sep 24, 2019
Andrew D. Zelenetz, MD, PhD
Several drugs have been developed in the lymphoid space in recent years, including BTK inhibitors and BCL-2 inhibitors, which have shown significant activity in mantle cell lymphoma (MCL), said Andrew D. Zelenetz, MD, PhD.
... to read the full story